News from Apogenix A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

May 04, 2016, 09:00 ET Apogenix to Present at Two Upcoming International Conferences

 Apogenix, a biopharmaceutical company developing next generation immuno-oncology therapeutics, announced today that Chief Executive Officer...


Mar 24, 2016, 09:00 ET Preclinical Efficacy Data of Apogenix' APG101 in Myelodysplastic Syndromes (MDS) Published in Oncotarget

Apogenix, a biopharmaceutical company developing next generation immuno-oncology therapeutics, announced today that the data published in the...


Feb 16, 2016, 09:00 ET Apogenix Receives €3 Million Grant for the Development of a Companion Diagnostic Test for Lead Immuno-Oncology Candidate APG101

 Apogenix, a biopharmaceutical company developing next generation immuno-oncology therapeutics, announced today that it has received funding...


Jan 14, 2016, 09:00 ET Apogenix Strengthens U.S. Patent Position for Lead Immuno-Oncology Candidate APG101

 Apogenix, a biopharmaceutical company developing next generation immuno-oncology therapeutics, announced today that it has received Notices of...


Jan 07, 2016, 09:00 ET Apogenix Receives First Milestone Payment from CANbridge Licensing Agreement and Signs Amendment to Include Taiwan

 Apogenix, a biopharmaceutical company developing next generation immuno-oncology therapeutics, announced today that the first milestone of its...


Dec 15, 2015, 09:00 ET Apogenix to Present at J.P. Morgan Healthcare Conference

Apogenix, a next generation immuno-oncology company, announced today that Chief Executive Officer Thomas Hoeger, Ph.D., will present at the 34th...


Oct 13, 2015, 09:00 ET Apogenix to Present at Three Upcoming International Conferences

 Apogenix, a next generation immuno-oncology company, announced today that Chief Executive Officer Thomas Hoeger, Ph.D., will present at the...


Jul 28, 2015, 09:00 ET Apogenix Enters into Cooperation with R-Biopharm to Develop Companion Diagnostic Tests for Immuno-Oncology Candidate APG101

Apogenix, a next generation immuno-oncology company, announced today that it has entered into an agreement with R-Biopharm, a global provider of...


Jul 15, 2015, 08:00 ET Apogenix Enters into Licensing Agreement with CANbridge Life Sciences for Immuno-Oncology Candidate APG101 in China

 Apogenix, a next generation immuno-oncology company, announced today that it has entered into an exclusive licensing agreement with CANbridge...


Jun 03, 2015, 09:00 ET Apogenix appoints Peter Willinger as new CFO

 Apogenix, a next generation immuno-oncology company, announced today the appointment of Peter Willinger as Chief Financial Officer. As head of...


Jun 01, 2015, 09:00 ET Apogenix to present at Jefferies 2015 Global Healthcare Conference

 Apogenix, a clinical stage biopharmaceutical company, announced today that Thomas Hoeger, Ph.D., Chief Executive Officer, will present at the...


Oct 28, 2014, 09:00 ET Apogenix - Positive Results from APG101 Phase II Clinical Trial Published in Clinical Cancer Research

 Apogenix, a clinical stage biopharmaceutical company, announced today that the final data of the completed phase II clinical trial with APG101...


Jan 13, 2014, 09:00 ET Apogenix' APG101 Demonstrates Significant Prolongation of Overall Survival in Biomarker-Positive Patients in Phase II Trial for the Treatment of Recurrent Glioblastoma

  Apogenix, a clinical stage biopharmaceutical company, announced today the successful completion of its...


Jan 07, 2014, 09:00 ET Apogenix to Present Phase II Results with APG101 for the Treatment of Recurrent Glioblastoma at Biotech Showcase in San Francisco

 Apogenix, a clinical stage biopharmaceutical company, announced today that Thomas Hoeger, Ph.D., Chief Executive Officer, will...


Dec 05, 2013, 09:00 ET Apogenix' APG350 Effectively Induces Apoptosis of Tumor Cells via TRAIL Pathway Independent of Fc-gamma Cross-Linking

 Apogenix, a clinical stage biopharmaceutical company, announced today that the data published in the December issue of Molecular Cancer...


Jul 02, 2013, 09:00 ET Apogenix Strengthens Patent Position for Apocept™ (APG101) in Europe and Canada

 Apogenix GmbH, a clinical stage biopharmaceutical company developing novel protein therapeutics for the treatment of cancer and inflammatory...


Feb 07, 2013, 09:00 ET Apogenix Receives FDA Orphan Drug Designation for Apocept™ to Treat Myelodysplastic Syndromes and Initiates Clinical Phase I Study

Apogenix GmbH, a clinical stage biopharmaceutical company developing novel protein therapeutics for the treatment of cancer and inflammatory...


Nov 06, 2012, 04:00 ET Apogenix's Apocept™ for Glioblastoma Multiforme Named One of "Top 10 Projects to Watch"

Apogenix, a clinical stage biopharmaceutical company developing novel protein therapeutics for the treatment of cancer and inflammatory...